Abstract

Mastocytosis is amyeloid neoplasm resulting fromthe excessive proliferation and accumulation of neoplastic mast cells in one or more organs. Systemic mastocytosis (SM) is a clonal hematopoietic stem cell neoplasm and a heterogeneous disease with several distinct subtypes. The majority of SM subtype in elderly patients belongs to advanced SM. Clinically, elderly patients with advanced SM carry a poor prognosis despite the use of cytoreductive therapy. Treatment with KIT tyrosine kinase inhibitors such as midostaurin and avapritinib has improved the outcome of advanced SMpatients. The safety and efficacy of KIT inhibitors were reviewed, and the future direction of clinical development was discussed.